Tadalafil
- Product NDC
- 70518-3434
- 11-digit product format
- 705183434
- Labeler code
- 70518
- Product ID
- 70518-3434_4f087df5-c1ba-22b4-e063-6294a90abb60
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Tadalafil
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- REMEDYREPACK INC.
- Application
- ANDA209654
- Marketing category
- ANDA
- Marketing start
- 2022-06-09
- Substance
- TADALAFIL
- Active strength
- 5 mg/1
- Pharmacologic classes
- Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 70518-3434 | 70518-3434-3 | D | Discontinued by firm | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209654-001 | TADALAFIL | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209654-002 | TADALAFIL | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209654-003 | TADALAFIL | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209654-004 | TADALAFIL | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2019-03-26 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209654-001 | AB1 |
| A209654-002 | AB1 |
| A209654-003 | AB1 |
| A209654-004 | AB1 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209654-001 | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209654-002 | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209654-003 | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209654-004 | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209654-001 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209654-002 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209654-003 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209654-004 | AB1 | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tadalafil | TADALAFIL | REMEDYREPACK INC. | 415bd983-86f3-4f38-917a-9805024f31cb | 2026-07-09 | Warnings, Adverse reactions | 209654 ANDA209654 70518-3434 |
| Tadalafil | TADALAFIL | REMEDYREPACK INC. | ad288e9d-020a-43a0-9c07-320c5c3bbc1e | 2026-05-27 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | 2c2ec257-06bc-4ca4-9cf3-d0f49980e374 | 2026-05-14 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | c835a34a-9bae-4d88-b951-1b78ab92f388 | 2026-05-13 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | f34e4747-28be-4ae5-ac9a-a825083b6a9b | 2026-01-12 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | PD-Rx Pharmaceuticals, Inc. | 7e236f83-14bf-4862-91fb-74d766aef6a9 | 2026-01-12 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | cf353da9-31c6-66c2-e053-2995a90a3bb0 | 2026-01-09 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Quallent Pharmaceuticals Health LLC | dc14daa3-cae9-4751-9034-b0e9c18054b4 | 2025-11-30 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Ajanta Pharma USA Inc. | 7e4cdac1-42cc-4038-a86b-4890962ed806 | 2025-10-10 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | 2354c3e2-7b5f-4fdd-bbf2-7fa3c57686f8 | 2025-09-25 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | 761dc0f8-2f65-4615-ab49-a4bcffd40ce9 | 2025-09-25 | Warnings, Adverse reactions | 209654 ANDA209654 |
| TADALAFIL | TADALAFIL | direct rx | b3ee8325-bcb2-43fd-e053-2a95a90a08c8 | 2025-07-09 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | 0a9cf85a-c17d-6890-e063-6394a90a93e9 | 2025-03-04 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | 85ed0cbc-df84-44df-a9eb-f9587dbc21df | 2024-08-21 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | 185a3284-3a4f-44d3-9278-98581d33f95b | 2024-08-08 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | A-S Medication Solutions | b1840f16-a7ea-44bd-b091-5268990aedb2 | 2024-02-20 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Aphena Pharma Solutions - Tennessee, LLC | 6213fd38-9580-4253-91d2-14c28a711c20 | 2023-08-28 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Asclemed USA, Inc. | 5ea24573-2d16-40d8-a46c-7b5fa8669e69 | 2023-03-28 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Proficient Rx LP | aa345972-40b4-415e-acb5-31b808a8d815 | 2023-03-01 | Warnings, Adverse reactions | 209654 ANDA209654 |
| Tadalafil | TADALAFIL | Aphena Pharma Solutions - Tennessee, LLC | 36350106-98bc-41fc-bede-8be5e6f54a8a | 2020-10-02 | Warnings, Adverse reactions | 209654 ANDA209654 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Tadalafil
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| TADALAFIL | 5 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 742SXX0ICT | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 403957 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 415bd983-86f3-4f38-917a-9805024f31cb | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| b90b74cb-f6c8-3798-d11c-73b8768b278a | Product name | 8 | 20250317 |
| 0fe0157c-95a7-4870-ae64-de9f3fa874ae | Product name | 1 | 20250227 |
| 20ae0006-d78c-4dba-9e3e-6ae424841903 | Product name | 1 | 20250127 |
| b86a08b7-54cc-440b-ad4a-3e530ccd8324 | Product name | 6 | 20230421 |
| 7a02e74a-2844-42af-84a8-96bae57351cf | Product name | 1 | 20230313 |
| 928d249c-35c3-4d88-a9ef-cf2f2e31b96f | Product name | 1 | 20220706 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70518-3434-0 | Tadalafil | 100 in 1 BOX | TABLET | 100 | 11 | |
| 70518-3434-1 | Tadalafil | 1 in 1 POUCH | TABLET | 1 | 11 | |
| 70518-3434-2 | Tadalafil | 250 in 1 BOX | TABLET | 250 | 11 | |
| 70518-3434-3 | Tadalafil | 30 in 1 BOTTLE, PLASTIC | TABLET | 30 | 11 | |
| 70518-3434-4 | Tadalafil | 30 in 1 BOTTLE, PLASTIC | TABLET | 30 | 11 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70518-3434-4 | EA - Each | 70518-3434 | d94fcc97-5de6-4c49-b33f-e93a188dea8f | 1 | 2026-02-05 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 70518-3434 | TADALAFIL TABLET [REMEDYREPACK INC.] | 6 | Current NDC, Legacy NDC, 5 package rows | 20240709_415bd983-86f3-4f38-917a-9805024f31cb.zip |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 403957 | tadalafil 5 MG Oral Tablet | PSN | 415bd983-86f3-4f38-917a-9805024f31cb | 11 |
| 403957 | tadalafil 5 MG Oral Tablet | SCD | 415bd983-86f3-4f38-917a-9805024f31cb | 11 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 70518-3434-0 | 70518343400 | 100 POUCH in 1 BOX (70518-3434-0) > 1 TABLET in 1 POUCH (70518-3434-1) | 100 pouch | 2022-06-09 | 0000-00-00 | No | No | Current |
| 70518-3434-1 | 70518343401 | 1 in 1 POUCH | Historical | |||||
| 70518-3434-2 | 70518343402 | 250 POUCH in 1 BOX (70518-3434-2) / 1 TABLET in 1 POUCH (70518-3434-1) | 250 pouch | 2022-06-23 | 0000-00-00 | No | No | Current |
| 70518-3434-3 | 70518343403 | 30 TABLET in 1 BOTTLE, PLASTIC (70518-3434-3) | 30 tablet | 2022-07-28 | 0000-00-00 | No | No | Current |
| 70518-3434-4 | 70518343404 | 30 TABLET in 1 BOTTLE, PLASTIC (70518-3434-4) | 30 tablet | 2023-01-03 | No | No | Current |